Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2022-06-10 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-06-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-10 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 7, 2022, by Aeglea BioTherapeutics, Inc. The key content is the submission of matters to a vote of security holders at the 2022 Annual Meeting of Stockholders. It details the voting results for director elections, ratification of the independent auditor, and advisory votes on executive compensation. The document is focused on reporting the official results of shareholder votes at a general meeting. It does not contain financial statements or detailed financial analysis, nor is it a proxy solicitation or a full annual report. The presence of detailed vote counts and the nature of the content clearly identify it as a Declaration of Voting Results & Voting Rights Announcement.
2022-06-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the receipt of a Refusal to File letter from the FDA regarding a Biologics License Application, details about regulatory interactions, and forward-looking statements. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is not a presentation, proxy, or earnings release. It is a regulatory announcement about a significant event affecting the company, fitting the category of Regulatory Filings (RNS). The document length (7021 characters) and content confirm it is a substantive filing but not a full financial report or other specific category. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2022-06-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.